Copyright
©The Author(s) 2023.
World J Clin Cases. Dec 6, 2023; 11(34): 8139-8146
Published online Dec 6, 2023. doi: 10.12998/wjcc.v11.i34.8139
Published online Dec 6, 2023. doi: 10.12998/wjcc.v11.i34.8139
Variable | ETV group (n = 30) | TAF group (n = 30) | P value |
eGFR (mL/min/1.73 m2) | -1.3 ± 3.2 | -1.5 ± 2.9 | 0.76 |
Serum creatinine (μmol/L) | 1.7 ± 5.6 | 2.1 ± 4.8 | 0.67 |
UPCR (mg/mmol) | -0.2 ± 0.6 | -0.1 ± 0.5 | 0.58 |
BMD at lumbar spine (%) | -2.1 ± 1.4 | -0.8 ± 1.2 | 0.004 |
BMD at hip (%) | -1.8 ± 1.3 | -0.6 ± 1.1 | 0.007 |
Serum calcium (mmol/L) | -0.01 ± 0.05 | -0.02 ± 0.04 | 0.42 |
Serum phosphate (mmol/L) | -0.03 ± 0.12 | -0.04 ± 0.11 | 0.69 |
Serum alkaline phosphatase (U/L) | -3.7 ± 12.4 | -4.3 ± 11.6 | 0.79 |
Serum parathyroid hormone (pg/mL) | -2.4 ± 8.7 | -3.1 ± 9.2 | 0.68 |
- Citation: Yuan GC, Chen AZ, Wang WX, Yi XL, Tu L, Peng F, Qiu ZH. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir. World J Clin Cases 2023; 11(34): 8139-8146
- URL: https://www.wjgnet.com/2307-8960/full/v11/i34/8139.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i34.8139